PASG Key Statistics, Chart & Performance
The current stock price of PASG is 9.21 USD. In the past month the price increased by 41.47%. In the past year, price decreased by -40.58%.
PASG Latest News, Press Relases and Analysis
PASG Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About PASG
Company Profile
Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
Company Info
PASSAGE BIO INC
One Commerce Square, 2005 Market Street, 39Th Floor
PHILADELPHIA PENNSYLVANIA 19103 US
CEO: Bruce Goldsmith
Employees: 60
Phone: 12678660312
PASSAGE BIO INC / PASG FAQ
What does PASG do?
Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 60 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.
What is the current price of PASG stock?
The current stock price of PASG is 9.21 USD. The price increased by 0.29% in the last trading session.
Does PASG stock pay dividends?
PASG does not pay a dividend.
How is the ChartMill rating for PASSAGE BIO INC?
PASG has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does PASSAGE BIO INC belong to?
PASSAGE BIO INC (PASG) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for PASG stock?
PASSAGE BIO INC (PASG) does not have a PE ratio as the earnings reported over the last twelve months were negative (-14.4).
What is the employee count for PASG stock?
PASSAGE BIO INC (PASG) currently has 60 employees.
PASG Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to PASG. When comparing the yearly performance of all stocks, PASG is a bad performer in the overall market: 70.79% of all stocks are doing better.
PASG Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PASG. PASG scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
PASG Financial Highlights
Over the last trailing twelve months PASG reported a non-GAAP Earnings per Share(EPS) of -14.4. The EPS decreased by -20% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71.79% | ||
| ROE | -148.61% | ||
| Debt/Equity | 0 |
PASG Forecast & Estimates
12 analysts have analysed PASG and the average price target is 40.39 USD. This implies a price increase of 338.57% is expected in the next year compared to the current price of 9.21.